SI3415515T1 - Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata - Google Patents

Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata

Info

Publication number
SI3415515T1
SI3415515T1 SI201031982T SI201031982T SI3415515T1 SI 3415515 T1 SI3415515 T1 SI 3415515T1 SI 201031982 T SI201031982 T SI 201031982T SI 201031982 T SI201031982 T SI 201031982T SI 3415515 T1 SI3415515 T1 SI 3415515T1
Authority
SI
Slovenia
Prior art keywords
methylcarbamate
fluorobenzyl
pyrazolo
pyrimidin
diamino
Prior art date
Application number
SI201031982T
Other languages
English (en)
Inventor
Franz-Josef Mais
Joachim Rehse
Winfried Joentgen
Konrad Siegel
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43536603&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3415515(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of SI3415515T1 publication Critical patent/SI3415515T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C325/00—Thioaldehydes; Thioketones; Thioquinones; Oxides thereof
    • C07C325/02—Thioketones; Oxides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201031982T 2009-11-27 2010-11-22 Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata SI3415515T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09177371 2009-11-27
EP18178602.1A EP3415515B1 (de) 2009-11-27 2010-11-22 Verfahren zur herstellung von methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat

Publications (1)

Publication Number Publication Date
SI3415515T1 true SI3415515T1 (sl) 2020-03-31

Family

ID=43536603

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201031762T SI2733142T1 (sl) 2009-11-27 2010-11-22 Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3il) pirimidin-5-il)metilkarbamata za uporabo kot farmacevtska učinkovina
SI201030773T SI2504334T1 (sl) 2009-11-27 2010-11-22 Postopek čiščenja (4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo-(3,4-b)piridin-3-il)piri midin-5-il)metilkarbamata
SI201031982T SI3415515T1 (sl) 2009-11-27 2010-11-22 Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata
SI201031061T SI2604608T1 (sl) 2009-11-27 2010-11-22 Postopek izdelave metil-(4,6-diamino-2(1-(2-fluorobenzil)-1H-pirazolo (3,4-b)piridin-3-il)-pirimidin-5-il)metil karbamata in njegovo čiščenje za uporabo kot farmacevtsko sredstvo

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI201031762T SI2733142T1 (sl) 2009-11-27 2010-11-22 Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3il) pirimidin-5-il)metilkarbamata za uporabo kot farmacevtska učinkovina
SI201030773T SI2504334T1 (sl) 2009-11-27 2010-11-22 Postopek čiščenja (4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo-(3,4-b)piridin-3-il)piri midin-5-il)metilkarbamata

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201031061T SI2604608T1 (sl) 2009-11-27 2010-11-22 Postopek izdelave metil-(4,6-diamino-2(1-(2-fluorobenzil)-1H-pirazolo (3,4-b)piridin-3-il)-pirimidin-5-il)metil karbamata in njegovo čiščenje za uporabo kot farmacevtsko sredstvo

Country Status (43)

Country Link
US (5) US8492544B2 (sl)
EP (5) EP2504334B1 (sl)
JP (4) JP5859451B2 (sl)
KR (2) KR101766931B1 (sl)
CN (2) CN104059064B (sl)
AR (1) AR079134A1 (sl)
AU (3) AU2010323227B2 (sl)
BR (3) BR122019002289B1 (sl)
CA (2) CA2936852C (sl)
CL (1) CL2012001329A1 (sl)
CO (1) CO6551708A2 (sl)
CR (1) CR20120280A (sl)
CU (1) CU24084B1 (sl)
CY (1) CY1115861T1 (sl)
DK (4) DK2504334T3 (sl)
DO (2) DOP2012000144A (sl)
EA (3) EA022813B1 (sl)
EC (2) ECSP12011921A (sl)
ES (4) ES2524826T3 (sl)
GT (1) GT201200158A (sl)
HK (2) HK1178899A1 (sl)
HR (4) HRP20141073T1 (sl)
HU (2) HUE026778T2 (sl)
IL (4) IL219683A (sl)
JO (3) JO3107B1 (sl)
LT (2) LT2733142T (sl)
MA (1) MA33783B1 (sl)
MX (1) MX2012005938A (sl)
MY (2) MY173711A (sl)
NZ (3) NZ600199A (sl)
PE (2) PE20121742A1 (sl)
PL (4) PL3415515T3 (sl)
PT (4) PT2504334E (sl)
RS (4) RS57790B1 (sl)
SI (4) SI2733142T1 (sl)
SM (1) SMT201400164B (sl)
TN (1) TN2012000257A1 (sl)
TR (1) TR201816146T4 (sl)
TW (1) TWI496781B (sl)
UA (1) UA110779C2 (sl)
UY (1) UY33048A (sl)
WO (1) WO2011064171A2 (sl)
ZA (1) ZA201204610B (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121742A1 (es) * 2009-11-27 2012-12-13 Adverio Pharma Gmbh PROCEDIMIENTO PARA LA PREPARACION DE {4,6-DIAMINO-2-[1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL]PIRIMIDIN-5-IL}METILCARBAMATO DE METILO Y SU PURIFICACION PARA SU USO COMO PRINCIPIO ACTIVO FARMACEUTICO
EP2796457B1 (en) 2009-11-27 2016-05-18 Genzyme Corporation Genz 112638 for treating Gaucher or Fabry disease in combination therapy
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
CA2856706C (en) 2011-11-25 2020-06-16 Bayer Pharma Aktiengesellschaft Method for producing substituted 5-fluoro-1h-pyrazolopyridines
EP3760629A1 (en) 2013-02-21 2021-01-06 Adverio Pharma GmbH Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
CN104327107A (zh) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
MX2017003664A (es) 2014-09-19 2017-07-13 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1.
WO2016113415A1 (en) 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
CN105367568B (zh) * 2015-11-18 2019-08-20 浙江京新药业股份有限公司 一种制备利奥西呱的方法
CN105294686B (zh) * 2015-11-30 2017-03-22 郑州大明药物科技有限公司 一种利奥西呱的制备方法
CN108463224A (zh) 2015-12-14 2018-08-28 铁木医药有限公司 sGC刺激剂用于胃肠功能障碍治疗的应用
US10414766B2 (en) * 2015-12-15 2019-09-17 Alembic Pharmaceuticals Limited Polymorph of Riociguat and its process for the preparation
CN108069960A (zh) * 2016-11-15 2018-05-25 江苏豪森药业集团有限公司 利奥西呱中间体的制备方法
WO2018096550A1 (en) * 2016-11-28 2018-05-31 Msn Laboratories Private Limited, R&D Center Process for the preparation of methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate and its polymorphs thereof
EP3554488A2 (en) 2016-12-13 2019-10-23 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2018130226A1 (zh) * 2017-01-16 2018-07-19 苏州科睿思制药有限公司 利奥西呱的新晶型及其制备方法和用途
EP3820476A1 (en) 2018-07-11 2021-05-19 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of mitochonrial disorders
CN115175666B (zh) * 2020-02-03 2024-04-26 阿德弗里奥药品有限责任公司 {4,6-二氨基-2-[5-氟-1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}氨基甲酸甲酯的纳米制剂
CN111689961A (zh) * 2020-06-01 2020-09-22 江苏华阳制药有限公司 一种利奧西呱的新晶型及其制备方法
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
CN112316932B (zh) * 2020-11-13 2022-03-01 中国石油大学(北京) 一种粗对苯二甲酸加氢精制催化剂及其制备方法和应用
CN112316968B (zh) * 2020-11-13 2022-03-01 中国石油大学(北京) 一种粗对苯二甲酸加氢精制催化剂及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950350A (en) * 1974-12-27 1976-04-13 Pfizer Inc. Penam-dimethylsulfoxide complex
US4970210A (en) * 1987-07-17 1990-11-13 Abbott Laboratories Triazinone lipoxygenase compounds
ATE120169T1 (de) * 1989-07-18 1995-04-15 Atochem Elf Sa Verfahren zur reinigung von 1,1-bis(4- chlorphenyl)-2,2,2-trichlorethanol.
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
BR9712523A (pt) * 1996-10-14 2000-05-09 Bayer Ag Novos derivados de pirazol heterociclilmetil-substituìdos
DE19642255A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
ES2172945T3 (es) * 1997-11-12 2002-10-01 Bayer Ag Imidazotriazinonas sustituidas en 2 con fenilo como inhibidores de fosfodiesterasas.
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE10057754A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
WO2002042299A1 (de) * 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Neue lactam-substituierte pyrazolopyridinderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057751A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
DE10122894A1 (de) * 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) * 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
US6738631B1 (en) 2002-05-06 2004-05-18 Nokia, Inc. Vision-guided model-based point-and-click interface for a wireless handheld device
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP4299573B2 (ja) * 2003-04-25 2009-07-22 東洋シヤッター株式会社 エレベータの扉装置
DE10222550A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
KR200342343Y1 (ko) 2003-11-17 2004-02-18 김강철 탄성체 유희용구
JP4978192B2 (ja) * 2004-04-01 2012-07-18 アステラス製薬株式会社 ピラジン誘導体およびその医薬的使用
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102009004245A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
UY33041A (es) * 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
PE20121742A1 (es) * 2009-11-27 2012-12-13 Adverio Pharma Gmbh PROCEDIMIENTO PARA LA PREPARACION DE {4,6-DIAMINO-2-[1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL]PIRIMIDIN-5-IL}METILCARBAMATO DE METILO Y SU PURIFICACION PARA SU USO COMO PRINCIPIO ACTIVO FARMACEUTICO
UY33040A (es) 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
KR20130132393A (ko) 2010-07-09 2013-12-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 고리-융합된 피리미딘 및 트리아진, 및 심혈관 질환의 치료 및/또는 예방을 위한 그의 용도
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
ES2592267T3 (es) 2011-05-06 2016-11-29 Bayer Intellectual Property Gmbh Imidazopiridinas e imidazopiridazinas sustituidas y su uso
WO2013004785A1 (de) 2011-07-06 2013-01-10 Bayer Intellectual Property Gmbh Heteroaryl-substituierte pyrazolopyridine und ihre verwendung als stimulatoren der löslichen guanylatcyclase
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
EP2822951B1 (de) 2012-03-06 2017-07-26 Bayer Intellectual Property GmbH Substituierte azabicyclen und ihre verwendung
KR20150121007A (ko) 2013-03-01 2015-10-28 바이엘 파마 악티엔게젤샤프트 트리플루오르메틸-치환된 고리-융합된 피리미딘 및 그의 용도

Also Published As

Publication number Publication date
US10351562B2 (en) 2019-07-16
EA022813B1 (ru) 2016-03-31
SI2733142T1 (sl) 2018-10-30
AU2017203023A1 (en) 2017-05-25
ES2693746T3 (es) 2018-12-13
IL251603A0 (en) 2017-06-29
GT201200158A (es) 2014-04-03
BR112012012617B8 (pt) 2021-05-25
ZA201204610B (en) 2014-09-25
AU2015243005B2 (en) 2017-06-01
IL219683A0 (en) 2012-07-31
HRP20151243T1 (hr) 2015-12-18
IL251601A0 (en) 2017-06-29
PL2733142T3 (pl) 2019-03-29
TWI496781B (zh) 2015-08-21
IL240878B (en) 2018-08-30
BR122019002291B8 (pt) 2021-05-25
JP2013512212A (ja) 2013-04-11
CU24084B1 (es) 2015-03-30
RS54433B1 (en) 2016-04-28
EP2504334A2 (de) 2012-10-03
PT2504334E (pt) 2014-12-03
AU2017203023B2 (en) 2018-11-08
LT3415515T (lt) 2020-03-10
ES2524826T3 (es) 2014-12-12
CL2012001329A1 (es) 2013-07-05
DK2604608T3 (en) 2015-12-07
CU20120082A7 (es) 2012-10-15
PL2604608T3 (pl) 2016-02-29
JP6514398B2 (ja) 2019-05-15
MX2012005938A (es) 2012-09-12
CA2936852A1 (en) 2011-06-03
CN104059064A (zh) 2014-09-24
ES2553035T3 (es) 2015-12-03
IL251601B (en) 2019-05-30
EP2504334B1 (de) 2014-10-01
RS59908B1 (sr) 2020-03-31
KR20120123258A (ko) 2012-11-08
MY173711A (en) 2020-02-17
US20180282329A1 (en) 2018-10-04
EA201891964A1 (ru) 2019-01-31
EP3699180A1 (de) 2020-08-26
RS53585B1 (en) 2015-02-27
SMT201400164B (it) 2015-01-15
BR122019002291B1 (pt) 2021-04-27
US10030014B2 (en) 2018-07-24
JP6371871B2 (ja) 2018-08-08
HRP20141073T1 (hr) 2015-01-02
JP6133931B2 (ja) 2017-05-24
TR201816146T4 (tr) 2018-11-21
EP2604608A2 (de) 2013-06-19
JO3651B1 (ar) 2020-08-27
JP2017081971A (ja) 2017-05-18
JP2018150383A (ja) 2018-09-27
PE20180203A1 (es) 2018-01-31
JO3650B1 (ar) 2020-08-27
US8853398B2 (en) 2014-10-07
WO2011064171A3 (de) 2011-08-11
JO3107B1 (ar) 2017-09-20
AU2010323227A1 (en) 2012-06-14
EP3415515B1 (de) 2019-12-25
EA031632B1 (ru) 2019-01-31
KR101861981B1 (ko) 2018-05-28
CO6551708A2 (es) 2012-10-31
AR079134A1 (es) 2011-12-28
BR112012012617B1 (pt) 2021-04-27
PT3415515T (pt) 2020-03-10
SI2604608T1 (sl) 2015-12-31
CN102791707B (zh) 2014-10-29
US20190284186A1 (en) 2019-09-19
PE20121742A1 (es) 2012-12-13
CN104059064B (zh) 2019-06-04
US20140288303A1 (en) 2014-09-25
UY33048A (es) 2011-06-30
IL219683A (en) 2015-09-24
CN102791707A (zh) 2012-11-21
DK3415515T3 (da) 2020-03-16
BR112012012617A2 (pt) 2015-09-08
HK1202292A1 (en) 2015-09-25
PT2733142T (pt) 2018-11-15
EP3415515A1 (de) 2018-12-19
CY1115861T1 (el) 2017-01-25
IL251603B (en) 2019-05-30
EP2733142B1 (de) 2018-08-01
AU2010323227B2 (en) 2015-11-19
EP2733142A2 (de) 2014-05-21
JP2015205887A (ja) 2015-11-19
NZ715101A (en) 2017-07-28
CA2781799A1 (en) 2011-06-03
NZ600199A (en) 2014-06-27
US20130310563A1 (en) 2013-11-21
EA201270636A1 (ru) 2013-01-30
ECSP12011921A (es) 2012-07-31
HUE040328T2 (hu) 2019-03-28
PL2504334T3 (pl) 2015-02-27
BR122019002289B1 (pt) 2021-09-28
MA33783B1 (fr) 2012-11-01
IL240878A0 (en) 2015-10-29
RS57790B1 (sr) 2018-12-31
WO2011064171A2 (de) 2011-06-03
LT2733142T (lt) 2018-10-10
HK1178899A1 (en) 2013-09-19
TW201200514A (en) 2012-01-01
US8492544B2 (en) 2013-07-23
MY180184A (en) 2020-11-24
SI2504334T1 (sl) 2014-11-28
TN2012000257A1 (en) 2013-12-12
EP2604608B1 (de) 2015-10-07
DOP2012000144A (es) 2012-11-15
CA2781799C (en) 2017-05-02
EP2604608A3 (de) 2013-08-07
AU2015243005A1 (en) 2015-11-05
PL3415515T3 (pl) 2020-06-01
DK2504334T3 (en) 2014-12-08
HUE026778T2 (en) 2016-08-29
KR101766931B1 (ko) 2017-08-09
UA110779C2 (uk) 2016-02-25
EP2733142A3 (de) 2014-10-15
JP5859451B2 (ja) 2016-02-10
US10570130B2 (en) 2020-02-25
CR20120280A (es) 2013-04-22
PT2604608E (pt) 2015-11-26
DK2733142T3 (en) 2018-11-19
HRP20181785T1 (hr) 2018-12-28
NZ625983A (en) 2016-02-26
DOP2020000062A (es) 2020-09-30
ES2775902T3 (es) 2020-07-28
EA036422B1 (ru) 2020-11-09
US20110130410A1 (en) 2011-06-02
HRP20200397T1 (hr) 2020-06-12
EA201590948A1 (ru) 2016-01-29
CA2936852C (en) 2019-10-29
ECSP18018453A (es) 2018-04-30
KR20170093992A (ko) 2017-08-16

Similar Documents

Publication Publication Date Title
SI3415515T1 (sl) Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata
SI2419428T1 (sl) Imidazo (1,2-a) piridin derivati kot FGFR kinaza inhibitorji za uporabo v terapiji
ZA200707136B (en) Imidazo (1,2-a) pyridine compounds as VEGF-R2 inhibitors
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
SI3178819T1 (sl) 5-Phenyl-(1,2,4)triazolo(1,5-A)pyridin-2-yl karboksamidi kot inhibitorji JAK
ZA201204028B (en) Imidazo[1.2-a]pyridine compounds, sysnthesis thereof, and methods of using same
SI2609082T1 (sl) Imidazo(4,5-c)kinolini kot inhibitorji dna-pk
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
IL206905A0 (en) 4-(pyrrolo[2,3-c]pyridine-3-yl)pyrimidin-2-
IL219826A0 (en) Novel polymorphic forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
IL233066A0 (en) Method for producing 1-(2-fluorobenzyl)-h1-pyrazolo [b-3,4]pyridine-3-formamidine hydrochloride
SG10201408059QA (en) 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
IL219712A0 (en) Novel solvates of methyl {4, 6 -diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b] pyridin - 3 - yl] pyrimidin - 5 -yl} carbamate
EP2490693A4 (en) Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
EP2565194A4 (en) Imidazo [1,2-A] pyridine
GB2464854B (en) Process for the preparation of risperidone